A Case of POEMS Syndrome and Associated Endocrinopathies: Hypogonadism and Subclinical Hypothyroidism

Kyle L. Yamamoto; Samuel T. Olatunbosun

doi:10.53941/ijctm.2025.1000013

Abstract

POEMS is a rare paraneoplastic syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes. Castleman disease (angiofollicular lymph node hyperplasia) and elevation of serum vascular endothelial growth factor (VEGF) are associated features as well. Pathogenesis of POEMS syndrome is still unclear, although a loss of balance between proinflammatory and anti-inflammatory cytokines is considered the underlying pathophysiology. Hypogonadism is the most common endocrinopathy encountered in POEMS syndrome. We report the case of a 45-year-old man with history of hypogonadism who developed Castleman disease. He was eventually diagnosed with POEMS syndrome upon developing polyneuropathy, his VEGF levels were elevated, and additionally, he was found to have subclinical hypothyroidism. Clinical and biochemical response to therapy and the course of his disease are presented. With treatment and normalization of his VEGF levels, his repeat thyroid function testing showed a decrease in his thyroid stimulating hormone levels to normal range. His hypogonadism continued to require testosterone replacement therapy. A potential role of cytokines and angiogenic factors in the development of the disease including the endocrinopathy component, is discussed. It is unclear whether VEGF has a role in the etiopathogenesis of the endocrinopathies or perhaps it is simply a marker of disease activity, with a low disease activity correlating with the recovery of the thyroid function. Further studies are needed to elucidate the underlying mechanisms, although we suspect it likely involves, at least in part, inflammatory cytokines and angiogenic factors.

References

1.
Dispenzieri, A.; Kyle, R.A.; Lacy, M.Q.; et al. POEMS syndrome: Definitions and long-term outcome. Blood 2003, 101, 2496–2506. https://doi.org/10.1182/blood-2002-07-2299.
2.
Lomas, O.C.; Streetly, M.; Pratt, G.; et al. The management of Castleman disease. Br. J. Haematol. 2021, 195, 328–337. https://doi.org/10.1111/bjh.17688.
3.
Gandhi, G.Y.; Basu, R.; Dispenzieri, A.; et al. Endocrinopathy in POEMS syndrome: The Mayo Clinic experience. Mayo Clin. Proc. 2007, 82, 836–842. https://doi.org/10.4065/82.7.836.
4.
Gherardi, R.K.; Bélec, L.; Soubrier, M.; et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996, 87, 1458–1465.
5.
Tomasso, A.; Innocenti, I.; Autore, F.; et al. VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response. Mediterr. J. Hematol. Infect. Dis. 2022, 14, e2022007. https://doi.org/10.4084/MJHID.2022.007.
6.
Pihan, M.; Keddie, S.; D’Sa, S.; et al. Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome. Neurol. Neuroimmunol. Neuroinflamm. 2018, 5, e486. https://doi.org/10.1212/NXI.0000000000000486.
7.
Caimari, F.; Keddie, S.; Lunn, M.P.; et al. Prevalence and Course of Endocrinopathy in POEMS Syndrome. J. Clin. Endocrinol. Metab. 2019, 104, 2140–2146. https://doi.org/10.1210/jc.2018-01516.
8.
Gherardi, R.; Baudrimont, M.; Kujas, M.; et al. Pathological findings in three non-Japanese patients with the POEMS syndrome. Virchows Arch A Pathol. Anat. Histopathol. 1988, 413, 357–365. https://doi.org/10.1007/BF00783029.
9.
Bardwick, P.A.; Zvaifler, N.J.; Gill, G.N.; et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: The POEMS syndrome. Report on two cases and a review of the literature. Medicine 1980, 59, 311–322. https://doi.org/10.1097/00005792-198007000-00006.
10.
Góth, M.I.; Hubina, E.; Raptis, S.; et al. Physiological and pathological angiogenesis in the endocrine system. Microsc. Res. Tech. 2003, 60, 98–106. https://doi.org/10.1002/jemt.10248.
11.
Yang, H.; Zhao, H.; Gao, X.; et al. Endocrine Evaluation in POEMS Syndrome: A Cohort Study. Front. Endocrinol. 2020, 11, 536241. https://doi.org/10.3389/fendo.2020.536241.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us